Compare Puma Biotechnology, Inc. (PBYI) vs Incyte Corporation (INCY) Stock

Puma Biotechnology, Inc. (PBYI) offers the better valuation at 9.3x trailing P/E (22.8x forward), making it the more compelling value choice. Analysts rate Puma Biotechnology, Inc. (PBYI) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Puma Biotechnology, Inc. (PBYI) is the cheapest at 9.3x versus Incyte Corporation at 15.8x. On forward P/E, Incyte Corporation is actually cheaper at 13.4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Incyte Corporation (INCY) delivered a total return of +27.2%, compared to -44.2% for Puma Biotechnology, Inc. (PBYI). A $10,000 investment in INCY five years ago would be worth approximately $13K today (assuming dividends reinvested). Over 10 years, the gap is even starker: INCY returned +37.8% versus PBYI's -87.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Puma Biotechnology, Inc. (PBYI) is the lower-risk stock at 0.54β versus Incyte Corporation's 0.61β — meaning INCY is approximately 13% more volatile than PBYI relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 22% for Puma Biotechnology, Inc. — giving it more financial flexibility in a downturn.

Incyte Corporation (INCY) is the more profitable company, earning 25.0% net margin versus 13.6% for Puma Biotechnology, Inc. — meaning it keeps 25.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26.1% versus 16.3% for PBYI. At the gross margin level — before operating expenses — INCY leads at 91.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.4x forward P/E versus 22.8x for Puma Biotechnology, Inc. — 9.4x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Incyte Corporation (INCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.61)). Both have compounded well over 10 years (INCY: +37.8%, PBYI: -87.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.